Nutritional status in oncological patients may differ according to several modifiable and non-
modifiable factors. Knowledge of the epidemiology of malnutrition/cachexia/sarcopenia may …

Basal cell carcinoma (BCC) is the most common malignant tumour in white populations.
Multidisciplinary experts from the European Dermatology Forum, the European Association …

Persistent cancer cells are the discrete and usually undetected cells that survive cancer drug
treatment and constitute a major cause of treatment failure. These cells are characterized by …

Glasdegib is a Hedgehog pathway inhibitor. This phase II, randomized, open-label,
multicenter study (ClinicalTrials. gov, NCT01546038) evaluated the efficacy of glasdegib …

Purpose To update the ASCO guideline for antiemetics in oncology. Methods ASCO
convened an Expert Panel and conducted a systematic review of the medical literature for …

Basal cell carcinoma (BCC) is the most common form of human cancer, with a continually
increasing annual incidence in the United States. When diagnosed early, the majority of …

Background Cemiplimab has shown substantial antitumour activity in patients with
metastatic cutaneous squamous cell carcinoma. Patients with locally advanced cutaneous …

Non-melanoma skin cancers (NMSCs) include basal cell carcinoma (BCC), squamous cell
carcinoma (SCC) and Merkel cell carcinoma (MCC). These neoplasms are highly diverse in …

Basal cell carcinoma (BCC) is the most common malignant tumour in white populations.
Multi-disciplinary experts from European Association of Dermato-Oncology (EADO) …

Background In the primary analysis of the ERIVANCE BCC trial, vismodegib, the first US
Food and Drug Administration–approved Hedgehog pathway inhibitor, showed objective …